Difference between revisions of "CT70"
(→References) |
|||
| Line 1: | Line 1: | ||
| + | Liver-expressed LXR-induced sequence (LeXis) is a functional lncRNA. | ||
| + | |||
==Annotated Information== | ==Annotated Information== | ||
===Name=== | ===Name=== | ||
| Line 14: | Line 16: | ||
===Characteristics === | ===Characteristics === | ||
| − | [[File:Schematic representation of the LeXis gene locus on Integrative Genome Viewer (IGV) showing histone marks from LICR ENCODE data.jpg|right|thumb|Schematic representation of the LeXis gene locus([https://www.ncbi.nlm.nih.gov/pubmed/27251289 | + | [[File:Schematic representation of the LeXis gene locus on Integrative Genome Viewer (IGV) showing histone marks from LICR ENCODE data.jpg|right|thumb|Schematic representation of the LeXis gene locus([https://www.ncbi.nlm.nih.gov/pubmed/27251289 <ref name="ref3" />])]] |
| − | LeXis, named as "Liver-expressed LXR-induced sequence", it's gene locus Lie in close proximity to the canonical LXR target gene Abca1 in mouse([https://www.ncbi.nlm.nih.gov/pubmed/27251289 | + | LeXis, named as "Liver-expressed LXR-induced sequence", it's gene locus Lie in close proximity to the canonical LXR target gene Abca1 in mouse([https://www.ncbi.nlm.nih.gov/pubmed/27251289 <ref name="ref3" />]), was distinct gene with Abca1, almost exclusively located in the insoluble nuclear pellet in fractionation studies, along with the known nuclear lncRNAs XIST and histone H3. |
===Expression=== | ===Expression=== | ||
| − | The highly expressed in primary mouse hepatocytes treated with GW3965([http://www.ncbi.nlm.nih.gov/pubmed/27251289 | + | The highly expressed in primary mouse hepatocytes treated with GW3965([http://www.ncbi.nlm.nih.gov/pubmed/27251289 <ref name="ref3" />]) and upregulated in OS(Osteosarcoma) tissues([http://www.ncbi.nlm.nih.gov/pubmed/28744406 <ref name="ref4" />]). |
===Regulation=== | ===Regulation=== | ||
| Line 25: | Line 27: | ||
===Function=== | ===Function=== | ||
| − | [[File:LeXis functions as a ceRNA of β-catenin.jpg|right|thumb|LeXis functions as a ceRNA of β-catenin([https://www.ncbi.nlm.nih.gov/pubmed/28744406 | + | [[File:LeXis functions as a ceRNA of β-catenin.jpg|right|thumb|LeXis functions as a ceRNA of β-catenin([https://www.ncbi.nlm.nih.gov/pubmed/28744406 <ref name="ref4" />])]] |
| − | LeXis binds with heterogeneous ribonucleoprotein Raly which contains both an RNA-binding domain and a leucine-zipper coiled domain, to affect the expression of srebf2 gene, resulting to the change of the level of SREBP-2(sterol regulatory element-binding protein), to modulate cholesterol metabolism([https://www.ncbi.nlm.nih.gov/pubmed/27251289 | + | LeXis binds with heterogeneous ribonucleoprotein Raly which contains both an RNA-binding domain and a leucine-zipper coiled domain, to affect the expression of srebf2 gene, resulting to the change of the level of SREBP-2(sterol regulatory element-binding protein), to modulate cholesterol metabolism([https://www.ncbi.nlm.nih.gov/pubmed/27251289 <ref name="ref3" /> |
| − | LeXis positively regulates CTNNB1 expression by functioning as a ceRNA against miR-199a to promote osteosarcoma growth([https://www.ncbi.nlm.nih.gov/pubmed/28744406 | + | LeXis positively regulates CTNNB1 expression by functioning as a ceRNA against miR-199a to promote osteosarcoma growth([https://www.ncbi.nlm.nih.gov/pubmed/28744406 <ref name="ref4" />. |
| + | LeXis expression was upregulated in OS tissues<ref name="ref3" />. | ||
===Disease=== | ===Disease=== | ||
| − | * osteosarcoma | + | * osteosarcoma<ref name="ref3" /> |
* colon adenocarcinoma <ref name="ref1" /> | * colon adenocarcinoma <ref name="ref1" /> | ||
| Line 38: | Line 41: | ||
==Labs working on this lncRNA== | ==Labs working on this lncRNA== | ||
| − | * No.4 Department of Orthopedics, Cangzhou Central HospitalCangzhou, Hebei Province, China | + | * No.4 Department of Orthopedics, Cangzhou Central HospitalCangzhou, Hebei Province, China<ref name="ref1" /><ref name="ref4" />. |
| − | * Department of Pathology and Laboratory Medicine, Howard Hughes Medical Institute, University of California, Los Angeles, California 90095, USA. | + | |
| + | * Department of Pathology and Laboratory Medicine, Howard Hughes Medical Institute, University of California, Los Angeles, California 90095, USA.<ref name="ref1" /><ref name="ref3" />. | ||
| + | |||
| + | * Weill Medical College of Cornell University, New York, NY 10021, USA. ytchen@med.cornell.edu<ref name="ref2" /> | ||
| + | |||
| + | * Department of Medicine, Division of Cardiology, University of California, Los Angeles, California 90095, USA<ref name="ref3" />. | ||
| + | |||
| + | * Departement of Human Genetics, University of California, Los Angeles, California 90095, USA<ref name="ref3" />. | ||
| + | |||
| + | * Ionis Pharmaceuticals, Carlsbad, California 92008, USA<ref name="ref3" />. | ||
| + | |||
| + | * Pasarow Mass Spectrometry Laboratory, NPI-Semel Institute, University of California, Los Angeles, California 90095, USA<ref name="ref3" />. | ||
| − | |||
<references> | <references> | ||
| − | <ref name="ref1"> Shahriyari L. Effect of normalization methods on the performance of supervised | + | <ref name="ref1"> Shahriyari L. Effect of normalization methods on the performance of supervised learning algorithms applied to HTSeq-FPKM-UQ data sets: 7SK RNA expression as a predictor of survival in patients with colon adenocarcinoma. Brief Bioinform.2017 Nov 3. doi: 10.1093/bib/bbx153.</ref> |
| − | learning algorithms applied to HTSeq-FPKM-UQ data sets: 7SK RNA expression as a | + | |
| − | predictor of survival in patients with colon adenocarcinoma. Brief Bioinform. | + | <ref name="ref2">Chen YT, Scanlan MJ, Venditti CA, Chua R, Theiler G, Stevenson BJ, Iseli C, Gure AO, Vasicek T, Strausberg RL, Jongeneel CV, Old LJ, Simpson AJ. Identification of cancer/testis-antigen genes by massively parallel signature sequencing. Proc Natl Acad Sci U S A. 2005 May 31;102(22):7940-5. doi: 10.1073/pnas.0502583102. Epub 2005 May 19.</ref> |
| − | 2017 Nov 3. doi: 10.1093/bib/bbx153. | ||
| − | </ref> | ||
| − | </ | ||
| − | |||
| + | <ref name="ref3">Sallam T, Jones MC, Gilliland T, Zhang L, Wu X, Eskin A, Sandhu J, Casero D, Vallim TQ, Hong C, Katz M, Lee R, Whitelegge J, Tontonoz P. Feedback modulation of cholesterol metabolism by the lipid-responsive non-coding RNA LeXis. Nature. 2016 Jun 2;534(7605):124-8. doi: 10.1038/nature17674. Epub 2016 May 11.</ref> | ||
| − | + | <ref name="ref4">Wang G, Cui T, Sun L, Peng N, Yang C. Long noncoding RNA LeXis promotes osteosarcoma growth through upregulation of CTNNB1 expression. Am J Cancer Res. 2017 Jul 1;7(7):1577-1587.</ref> | |
| + | </references> | ||
Revision as of 08:03, 27 November 2020
Liver-expressed LXR-induced sequence (LeXis) is a functional lncRNA.
Contents
Annotated Information
Name
Approved symbol: CT70
Approved name: cancer/testis associated transcript 70
HGNC ID: HGNC:37195
Previous names: cancer/testis antigen 70
Alias symbols: LeXis
RefSeq ID: XR_001746866
Characteristics
_showing_histone_marks_from_LICR_ENCODE_data.jpg)
LeXis, named as "Liver-expressed LXR-induced sequence", it's gene locus Lie in close proximity to the canonical LXR target gene Abca1 in mouse([1]), was distinct gene with Abca1, almost exclusively located in the insoluble nuclear pellet in fractionation studies, along with the known nuclear lncRNAs XIST and histone H3.
Expression
The highly expressed in primary mouse hepatocytes treated with GW3965([1]) and upregulated in OS(Osteosarcoma) tissues([2]).
Regulation
Please input evolution information here.
Function
LeXis binds with heterogeneous ribonucleoprotein Raly which contains both an RNA-binding domain and a leucine-zipper coiled domain, to affect the expression of srebf2 gene, resulting to the change of the level of SREBP-2(sterol regulatory element-binding protein), to modulate cholesterol metabolism([https://www.ncbi.nlm.nih.gov/pubmed/27251289 [1]
LeXis positively regulates CTNNB1 expression by functioning as a ceRNA against miR-199a to promote osteosarcoma growth([https://www.ncbi.nlm.nih.gov/pubmed/28744406 [2].
LeXis expression was upregulated in OS tissues[1].
Disease
Evolution
Please input evolution information here.
Labs working on this lncRNA
- Department of Pathology and Laboratory Medicine, Howard Hughes Medical Institute, University of California, Los Angeles, California 90095, USA.[3][1].
- Weill Medical College of Cornell University, New York, NY 10021, USA. ytchen@med.cornell.edu[4]
- Department of Medicine, Division of Cardiology, University of California, Los Angeles, California 90095, USA[1].
- Departement of Human Genetics, University of California, Los Angeles, California 90095, USA[1].
- Ionis Pharmaceuticals, Carlsbad, California 92008, USA[1].
- Pasarow Mass Spectrometry Laboratory, NPI-Semel Institute, University of California, Los Angeles, California 90095, USA[1].
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 Sallam T, Jones MC, Gilliland T, Zhang L, Wu X, Eskin A, Sandhu J, Casero D, Vallim TQ, Hong C, Katz M, Lee R, Whitelegge J, Tontonoz P. Feedback modulation of cholesterol metabolism by the lipid-responsive non-coding RNA LeXis. Nature. 2016 Jun 2;534(7605):124-8. doi: 10.1038/nature17674. Epub 2016 May 11.
- ↑ 2.0 2.1 2.2 2.3 Wang G, Cui T, Sun L, Peng N, Yang C. Long noncoding RNA LeXis promotes osteosarcoma growth through upregulation of CTNNB1 expression. Am J Cancer Res. 2017 Jul 1;7(7):1577-1587.
- ↑ 3.0 3.1 3.2 Shahriyari L. Effect of normalization methods on the performance of supervised learning algorithms applied to HTSeq-FPKM-UQ data sets: 7SK RNA expression as a predictor of survival in patients with colon adenocarcinoma. Brief Bioinform.2017 Nov 3. doi: 10.1093/bib/bbx153.
- ↑ Chen YT, Scanlan MJ, Venditti CA, Chua R, Theiler G, Stevenson BJ, Iseli C, Gure AO, Vasicek T, Strausberg RL, Jongeneel CV, Old LJ, Simpson AJ. Identification of cancer/testis-antigen genes by massively parallel signature sequencing. Proc Natl Acad Sci U S A. 2005 May 31;102(22):7940-5. doi: 10.1073/pnas.0502583102. Epub 2005 May 19.
